Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Sana regains some of its shine
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
Two allogeneic cell therapy switches in a day
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
Cellular Biomedicine draws a line under its past
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
Off-the-shelf Car-T from Caribou does enough at six months
Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.
